Tag: 7751DMT20Poster-Disease-modifying TherapyDaniel Kantor

Poster-Disease-modifying Therapy

Number-Needed-to-Treat (NNT) to Prevent One Relapse in Recent Teriflunomide-Controlled Clinical Trials in Relapsing MS

Background: Over the past two and a half decades, there has been an exponential increase in FDA approvals of treatments for relapsing forms...

Read More